News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Keryx Biopharmaceuticals Announces Appointment Of Jack Kaye, CPA, To Board Of Directors
September 20, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) today announced the appointment of Jack Kaye, CPA, to the Company's Board of Directors.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Layoff Tracker
Amgen lays off around 40 employees
July 26, 2026
·
70 min read
·
BioSpace Editorial Staff
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
·
3 min read
·
Gabrielle Masson
IPO
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
July 24, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
July 24, 2026
·
4 min read
·
Annalee Armstrong
